A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Danish Gynecological Cancer Group
National Cancer Institute (NCI)
AstraZeneca
University of Oklahoma
AstraZeneca
GlaxoSmithKline
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
NETRIS Pharma
Huazhong University of Science and Technology